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Radiation can directly impair hypothalamic, pituitary, thyroid, pancreatic and gonadal function as well as predisposing to development of hyperparathyroidism, and thyroid adenomas or carcinomas. Cytotoxic chemotherapy can damage the gonad, and both irradiation and cytotoxic chemotherapy may interfere with the normal growth of bone. These complications of treatment lead to clinical presentations including infertility, gynaecomastia, hypogonadism, impaired growth, failure to undergo normal pubertal development, precocious puberty, hyperparathyroidism, hypothyroidism, thyroid tumours, diabetes melli-tus1 and varying degrees of hypopituitarism.
HYPOTHALAMOPITUITARY AXIS Deficiency of one or more anterior pituitary hormones is now a well-recognized sequel to external radiotherapy to the hypothalamopituitary axis. This may occur in patients treated for non-functioning pituitary adenomas, hormone secreting pituitary adenomas and craniopharyngiomas. Anterior pituitary hormone deficiencies have also been reported when the hypothalamopituitary axis has been within the radiation field during treatment of nasopharyngeal cancer and intracranial tumours distant from the pituitary fossa. Children at risk2 include those irradiated for brain tumours, retinoblastoma, and acute lymphoblastic leukaemia (ALL) and those who receive total body irradiation3 in preparation for a bone marrow transplant.
Growth hormone (GH) secretion is the most vulnerable of the anterior pituitary hormones to irradiation, irrespective of whether the damage is hypothalamic or pituitary in site.
In a large series4 of adult patients with tumours of the pituitary or closely related anatomical sites, pituitary function was studied annually for up to 10 years after external radiotherapy by a three-field technique, in which 3750-4250cGy (rad) was given in 15 or 16 fractions over [20] [21] [22] days. Before radiotherapy 18% of patients had normal GH secretion, 21 % had normal gonadotropin secretion, 57% had normal corticotropin reserve and 80% had normal thyrotopin secretion. Life-table analysis demonstrated increasing incidences of all anterior pituitary hormone deficiencies with time: by 5 years all patients were GH deficient, 91% were gonadotropin deficient, 77% were corticotropin deficient and 42% were thyrotropin deficient. At 8 years respective incidences of deficiencies were 100%, 96%, 84% and 49%. Although anterior pituitary hormone deficiencies most commonly developed in the order of GH, gonadotropin, corticotropin, thyrotropin (61 % of patients), other sequences were evident. Most notably, corticotropin deficiency sometimes occurred before gonadotropin deficiency. Radiation-induced hyperprolactinaemia was common4.
Site and nature of radiation damage
Although diabetes insipidus has not been reported after external irradiation to the hypothalamopituitary axis, several studies2 indicate that the hypothalamus is more vulnerable to radiation damage than the pituitary, so that normal GH responses to GH releasing hormone (GHRH) may be seen in the presence of subnormal GH responses to an insulin tolerance test (ITT).
Raised prolactin levels, subnormal thyroid function in the presence of a normal but delayed thyroid stimulating hormone (TSH) rise after thyrotropin releasing hormone (TRH), subnormal gonadal function in the presence of a normal gonadotropin response to gonadotropin releasing hormone (GnRH) and subnormal adrenocortical function in the presence of a normal adrenocorticotropin (ACTH) response to corticotropin releasing factor 41 (CRF41) have also been reported. Finally, the severe blunting of physiological GH secretion despite normal GH responses to pharmacological stimuli, both in the monkey and in man, strongly suggests a hypothalamic locus for the defect.
Studies of hypothalamic blood flow5 suggest that direct injury to hypothalamic neurons rather than reduced cerebral blood flow is the major cause of progressive hypothalamicpituitary dysfunction after fractionated cranial irradiation.
Neuropharmacology has provided an additional tool to explore the pathophysiology of radiation injury. Ogilvy-Stuart et al.6 investigated the impact of irradiation on the neuroregulatory control of GH secretion by manipulating C/i~J R Soc Med 1997; 90:192-199 cholinergic tone in young adults rendered GH deficient in childhood by cranial irradiation: this approach is based on the established contribution of cholinergic input in modifying somatostatin tone and thereby GH secretion.
The number of patients was small but the results were consistent with dual sites of radiation damage. Somatostatin tone was subnormal and endogenous GHRH secretion was also low. The somatostatin tone could be increased by cholinergic manipulation; thus patients with radiationinduced GH deficiency might respond to treatment with GHRH analogues or other GH releasing peptides/nonpeptides.
Radiation schedule and pituitary function The total dose of radiation delivered to the hypothalamopituitary region is a major determinant of the incidence of anterior pituitary hormone deficiencies. In the treatment of pituitary disease, the low-dose regimen of 2000 cGy in eight fractions over 11 days is associated with a substantially lower incidence of all deficiencies than is 3500-4500 cGy in fifteen fractions over 21 days. The total dose of radiation directed at the hypothalamopituitary axis is not, however, the only factor determining the incidence of hypopituitarism. Our data indicate that a dose of 3000 cGy delivered in eight fractions over 11 days to the whole brain has a deleterious effect on gonadotropin secretion similar to that of 3700-4000 cGy administered to the hypothalamopituitary region in fifteen fractions over 21 days in other words, fraction size is important7. Similarly 14 out of 17 children who received cranial irradiation in a dose of 2500 cGy in ten fractions over 16 days had a subnormal GH response to an ITT, compared with 1 out of 9 who received a dose of 2400 cGy in twenty fractions over 4 weeks. Despite a nearly identical total radiation dose, the incidence of GH deficiency differed significantly because of the change in fraction size8.
The extent of hypothalamopituitary dysfunction is dose dependent, GH deficiency occurring at lower doses of irradiation and panhypopituitarism after high doses. The speed with which individual pituitary hormone deficiencies occur is also dose dependent. The higher the radiation dose, the earlier the pituitary hormone deficit will develop after treatment.
Apart from radiation dose, timing of onset of radiationinduced pituitary hormone deficit is influenced by preirradiation pituitary hormone status as illustrated by the evolution of radiation-induced GH deficiency9. This information may help the clinician to predict the likelihood and timing of pituitary hormone deficits in patients receiving irradiation to the hypothalamic-pituitary region.
PRECOCIOUS PUBERTY
Doses of cranial irradiation exceeding 5000 cGy to the hypothalamic-pituitary axis may render a child gonadotropin deficient. Paradoxically, lesser doses can provoke early puberty. This phenomenon has arisen in both boys and girls irradiated with 2500-4750cGy for a brain tumour'0.
In 46 GH deficient children previously irradiated for a brain tumour not involving the hypothalamic-pituitary axis there was a linear association between age at irradiation and age at onset of puberty. Puberty began at a mean of 8.51 years in girls and 9.21 years in boys plus 0.29 years for every year of age at irradiation. For example, the estimated age at onset of puberty in a boy irradiated at 2 years of age would be 9.79 years and that for a boy irradiated at 9 years of age would be 11.82 years. In the context of GH deficiency, which is usually associated with a delay in the onset of puberty, this is abnormal.
The largest number of children available for the study of pubertal timing after irradiation are those treated for childhood leukaemia (dose of irradiation 1800-2400 cGy). Early puberty is common but almost confined to girls; in boys it is no more frequent than in a normal population. This sexual dichotomy has been attributed to fundamental differences in the interaction between the central nervous system (CNS) and hypothalamic function. It has been postulated that the CNS restraint on the onset of puberty is more readily disrupted in girls than in boys by any insult including irradiation. At the doses of irradiation employed in the treatment of brain tumours (2500-4700cGy), however, radiation-induced early puberty is not restricted to girls.
Early puberty after irradiation probably results from disinhibition of cortical influences on the hypothalamus. Puberty then proceeds through the increased frequency and amplitude of GnRH pulsatile secretion by the hypothalamus. The impact of early puberty in a child with radiation-induced growth failure is to foreshorten the time available for GH therapy. Consequently some of these children are now treated with a combination of a GnRH analogue and GH. To halt the progression of puberty is not difficult, but we do not yet know the impact of this approach on final height.
THYROID CANCER
In 1950 Duffy and Fitzgerald1l reported that 9 of a series of 28 children with thyroid carcinoma had received irradiation for thymic enlargement previously, and raised the possibility that irradiation was an aetiological factor in the development of thyroid tumours. Subsequently large-scale surveys were undertaken, all of which confirmed unequivocally a causal relationship between external irradiation of the neck in childhood and thyroid cancer. Important determinants of cancer risk are radiation dose, age at exposure and time since exposure12. Thus, after neck irradiation, young children are more vulnerable than older children to the subsequent development of thyroid cancer, and all children are much more at risk than adults. Within certain limitations, the risk of thyroid cancer appears proportional to the dose of radiation. After analysing the data from several large studies, Maxon et al.13 concluded that the risk of thyroid cancer after 600 and 1200 cGy was, respectively, almost 2.5-fold and 5-fold greater than after 200 cGy. The risk of carcinogenesis is present over a wide range of radiation doses and extends for at least 50 years.
Thus, Ron et al.14 identified 98 thyroid tumours during follow-up of 10 834 persons irradiated for tinea capitis during childhood compared with 57 among a population of 10834 non-exposed matched individuals and 5392 sibling comparison subjects. An estimated thyroid dose of 9cGy was linked to a fourfold increase in malignant thyroid tumours. The dose-response relationship was consistent with linearity. Histologically, the great majority of radiation-induced thyroid cancers are well-differentiated papillary carcinomas, but follicular tumours also occur. An important factor in the prognosis for spontaneously occurring thyroid cancer is the size of the lesion at diagnosis, those less than 1.5 cm in diameter when detected having little or no effect on lifespan. Many radiationinduced tumours are small, but about half are greater than 1.5 cm in diameter; multicentric disease, local invasion and distant metastases are more likely than with tumours in unirradiated patients. However, when irradiated patients are matched for age, sex and extent of disease with unirradiated patients, there is no difference in disease-free interval or survival15.
Confirmation of the relationship between irradiation and thyroid cancer is provided by accidental irradiation exposure. During the initial period after the Chernobyl accident, large amounts of radioactive iodine were released in fallout, resulting in serious exposure to the thyroid gland in the residents of areas around the nuclear power station. Beginning in 1990, a definite increase in the incidence of thyroid cancer was noted in children of the Republic of Belarus16.
Benign nodules
Abnormalities of thyroid morphology other than cancer are frequently present in patients exposed to radiation. These include focal hyperplasia, single or multiple adenomas, chronic lymphocytic thyroiditis, colloid nodules and fibrosis. Investigators use many different definitions for benign thyroid tumours; some separate and others combine adenomas and colloid nodules, hence the large differences palpable thyroid abnormalities occur in about 20-30% of an irradiated population as compared with a 1-5% prevalence of palpable nodular thyroid disease within the general population. Benign thyroid nodularity occurs much more frequently in an irradiated population than thyroid cancer, but the exact incidence is less precisely documented. After surgical removal, radiation-induced benign thyroid nodules have a high recurrence rate similar to that reported among unirradiated patients with similar lesions17. Treatment with thyroid hormone in order to suppress TSH levels after thyroid surgery decreases the incidence of recurrence of benign radiation-induced nodules17.
THYROID DYSFUNCTION
Most accumulated data about radiation-induced hypothyroidism are derived from studies in patients treated for lymphomas18 or head and neck cancer. These individuals have generally received doses of irradiation in the range of 3000 and 5000 cGy given in multiple fractions over several weeks. Following a radiation dose to the neck of between 4000 and 5000 cGy over 4-5 weeks, about 25% of patients show a raised TSH and a low thyroxine concentration, whilst in a further 41% there is a raised TSH concentration in the presence of normal thyroxine18. The inclusion of a TRH test to amplify minor abnormalities in basal TSH secretion has revealed a further group of patients who show an exaggerated TSH response to TRH but normal basal TSH and thyroxine concentrations. Occasionally thyroid function returns to normal several years after documented radiationinduced dysfunction.
Apart from patients receiving neck irradiation for lymphoma or head and neck cancer, there are other groups who are vulnerable to radiation-induced thyroid dysfunction or thyroid tumours. Direct irradiation is received by the thyroid gland during the spinal component of craniospinal irradiation administered to treat certain childhood brain tumours. Similarly at risk are children who receive total body irradiation in preparation for bone marrow transplantation. Total body irradiation has been given in single dose exposures of 750-1000 cGy, and more recently in fractionated exposures of total doses ranging from 1200 to 1575 cGy over 3-7 days19. Of 116 children who received transplants for malignancy after preparation with cyclophosphamide and total body irradiation, 18% developed compensated thyroid dysfunction (raised TSH, normal thyroxine), 11% developed frank hypothyroidism, and two developed thyroid tumours 4 and 8 years later3. The treatment of hypothyroidism (raised TSH, low thyroxine), whether it be due to radiation-induced thyroid damage or any other cause, is thyroxine. A similar therapeutic in reported risk estimates. Certain studies suggest that approach is justified for patients with compensated thyroid dysfunction (raised TSH, normal thyroxine) irrespective of whether or not the latter state represents a mild but significant form of hypothyroidism or merely a biochemical abnormality. Support for this view is derived from the observation that a raised TSH in the presence of radiationdamaged thyroid tissue is carcinogenic.
Chemotherapy and thyroid function Although there is no conclusive evidence that any cytotoxic drug alters thyroid function to the extent of causing clinical hypothyroidism or hyperthyroidism, both 5-fluorouracil and L-asparaginase can modify circulating thyroid hormone levels. 5-fluorouracil increases total T4 and T3 levels while L-asparaginase decreases the total T4 level. Patients receiving 5-fluorouracil are clinically euthyroid and have a normal free thyroxine index and TSH. The drug either modifies the concentration of one or more thyroid hormone binding proteins or causes a qualitative change in their binding capacity. L-asparaginase has widespread effects on protein and DNA synthesis. It causes transient thyroxinebinding globulin (TBG) deficiency by diminishing hepatic synthesis of TBG, and appears to decrease free T4 concentrations into the hypothyroid range by inhibiting TSH secretion by the pituitary gland.
Atkins et al.20 described hypothyroidism in 7 of 34 patients with advanced neoplasms who had received interleukin 2 (IL-2) and lymphokine-activated killer (LAK) cells. It was suggested that IL-2 and LAK cells exacerbate pre-existing autoimmune thyroiditis and thus cause hypothyroidism in susceptible individuals.
Chemotherapy may potentiate the adverse impact of radiation on thyroid function. Ogilvy-Stuart et al.21 showed a higher incidence of thyroid dysfunction in children receiving adjuvant cytotoxic chemotherapy after craniospinal irradiation for a brain tumour than in children receiving craniospinal irradiation alone.
PARATHYROID GLAND
Several studies point to an increased risk of hyperparathyroidism in patients who have received neck irradiation. The evidence for a causal relationship consists largely of retrospective data showing that patients with hyperparathyroidism are more likely than normocalcaemic controls to have received irradiation to the neck in the past. The latency period seems very long-25-47 years.
Whether radiation exposure is a risk factor for hyperparathyroidism has been hard to establish with certainty, partly because many hyperparathyroid individuals remain symptomless and escape clinical detection. Recently Schneider et al. 22 reviewed data from 2555 people who received external irradiation to the head and neck area for 1939 and 1962. There were 36 confirmed cases of hyperparathyroidism. The relative risk increased significantly by 0.1 1 per cGy but the confidence interval was wide (95% confidence interval, 0.0-17.2). The demonstration of a dose-response relationship within an irradiated cohort supports the hypothesis of a causal association between radiation exposure and hyperparathyroidism. The clinical implication is that individuals who have received neck irradiation should have their calcium level monitored regularly.
RADIATION-INDUCED GONADAL DAMAGE

Testis
Exposure to X-rays, neutrons and radioactive materials can destroy germinal cells. Under acute conditions of exposure, spermatogenesis may eventually recover, provided the dose is not excessive.
Irradiation of the testis during radiotherapy usually involves fractionated exposures. Under certain conditions fractionation causes more stem-cell killing than do single treatments, although this has not been proven in human beings. Hahn et al.23 did serial semen examinations in 11 cancer patients who had received large pelvic field irradiation or interstitial 1251 seeds implanted in the prostate. The total calculated dose to the testes ranged from 118 to 228 cGy in 24-35 fractions. All patients had temporary aspermia, beginning at about 3 months postirradiation. Recovery of spermatogenesis was first noted between 10 and 18 months after irradiation in five patients.
The same group24 studied a cohort of patients who received total fractionated doses of 19-178cGy to the remaining testis following unilateral orchidectomy for seminoma. Azoospermia occurred in 10 of 14 who received more than 65 cGy to the testis. Sperm reappeared in the semen within weeks of the start of treatment.
With fractionated courses of irradiation, azoospermia has been induced by a testicular dose as low as 35 cGy. After a radiation dose of between 200 and 300 cGy, the primary impact of the damage is on the germinal epithelium with recovery of spermatogenesis sometimes delayed for 10 years or more. Leydig cell function is intact as judged by a normal serum testosterone, although in some patients the normal hormone concentration may be maintained only by a slightly raised circulating luteinizing hormone (LH) concentration. As the testicular irradiation dose is increased to several thousand cGy25 (i.e. 3000 cGy), the serum testosterone often becomes frankly low and androgen replacement therapy may be necessary. Radiation-induced testicular damage is also a recognized complication of radioactive iodine therapy for thyroid cancer. Serious impairment of spermatogenesis seems restricted to men 1 benign conditions before their sixteenth birthday between having multiple doses totalling over 100 mCi (equivalent to a testicular radiation dose of 50-100 cGy). Men receiving total body irradiation (TBI) and high dose chemotherapy in preparation for a bone marrow transplant all develop azoospermia. The TBI dose, ranging from about 800 to 1400 cGy in total, may be given in single or multiple fractions. In some patients the azoospermia may reverse with time but the exact frequency of this phenomenon has not yet been documented26.
Most boys with leukaemic relapse of the testes receive direct testicular irradiation with a total dose of between 2000 and 2400 cGy. The young prepubertal boy seems most vulnerable to the development of severe and persistent testicular dysfunction. The germinal epithelium is completely ablated in all, and Leydig cell function is seriously affected in most. However, gonadal damage may not be associated with abnormal gonadotropin concentrations in prepubertal life, either basally or after GnRH stimulation; these develop during the peripubertal years and will often first occur around the age of 9-10 years. The serum testosterone concentration is low, as expected in a prepubertal boy, but a testosterone response to an acute bolus of human chorionic gonadotropin (hCG) is subnormal or absent. Most boys require androgen replacement for normal pubertal development. Initiation of androgen replacement should be considered at about 12-13 years of age; the requirement will be permanent.
Lower doses of testicular irradiation are received by boys undergoing TBI for a bone marrow transplant and those receiving spinal fields of irradiation as part of a craniospinal radiotherapy schedule for a brain tumour. The degree of damage inflicted by the testicular irradiation i.e. germinal epithelial damage, with or without Leydig cell dysfunction-depends on the radiation dose and the age and pubertal stage of the boy19.
Ovary When girls and women are irradiated, the response of the ovary involves a fixed population of cells which, once destroyed, cannot be replaced. Effects on fertility are most readily explained on the basis of a reduction in the fixed pool of oocytes. While a permanent menopause can be caused by a total radiation exposure of about 600 cGy in women aged 40 years or more, radiotherapists' estimate of the 50% probability level for permanent sterility is approximately 2000cGy over a 6-week period in young women. If the radiation dose is delivered over a greater number of fractionated doses, the damage to the ovary and consequent chance of infertility is likely to be less. In agreement with this, Doll and Smith27 found that 97% of 2068 women never menstruated again after two to four fractionated exposures to a total dose of 360-720 cGy (estimated ovarian dose).
The treatment of Hodgkin's disease is influenced by the extent of the disease. Certain patients receive irradiation to the lymph nodes along the iliac vessels. Since the ovaries lie in this area, they receive a dose of about 3500 cGy, which inevitably causes ovarian failure.
Transposition of the ovaries (oophoropexy) before irradiation, with a consequent reduction in the dose delivered to the shielded ovaries to a maximum of 600cGy over 12-45 days, has decreased the incidence of amenorrhoea by over half. Nonetheless, the exact benefit to be derived from oophoropexy in women requiring inverted 'Y' therapy is controversial. The extent of the disease needs to be carefully staged before oophoropexy is contemplated, and then the procedure needs to be done with great accuracy and care.
There have been few investigations of ovarian function following abdominal irradiation in childhood. After 2000-3000 cGy over 25 44 days to both ovaries, ovarian failure is almost universal. Morphological studies have revealed striking inhibition of follicular growth and severe reduction in the number of oocytes. Recent work has indicated that the spinal component of craniospinal irradiation for the treatment of brain tumours and TBI for bone marrow transplantation3 may cause ovarian dysfunction via radiationinduced ovarian damage. The patients present with either failure to start or failure to complete pubertal development, or later in adult life with a premature menopause. On occasions the ovarian failure proves reversible. The LD50 for the human oocyte has been estimated28 not to exceed 400 cGy; and, in conjunction with information about the position of the ovaries in relation to the radiation field, the predicted age at ovarian failure can be calculated. This may provide a factual basis for fertility counselling in such patients.
Radiation and the uterus
In those women irradiated during childhood whose ovarian function has been preserved but whose uterus was included in the radiation field, the risk of miscarriage or a low birth weight infant is greatly increased29.
Following an irradiation dose in childhood of 2000-3000 cGy to the whole abdomen, these women have a significant reduction in uterine length and an endometrium which is unresponsive to physiological serum levels of oestradiol and progesterone attained by exogenous administration. Doppler signals from the uterine arteries are absent in most. Whether this is a consequence of primary damage to the microvasculature of the uterus and associated blood supply is not yet clear. As appropriate vascularization and subsequent growth of the endometrium are essential, however, for implantation and successful continuation of pregnancy, it is unlikely that women who have received a significant dose of abdominal irradiation in childhood will be able to sustain a pregnancy to term. This has implications for in vitro fertilization with donor oocytes in irradiated women with concomitant ovarian failure.
CHEMOTHERAPY-INDUCED GONADAL DAMAGE
Testis
Several different cytotoxic drugs clearly damage the gonad. The main culprits are alkylating drugs such as cyclophosphamide and chlorambucil, but nitrosoureas, procarbazine, vinblastine, cytosine arabinoside and cisplatin have all been incriminated.
The extent of the damage and potential for recovery depend on the nature of the drugs received and the dosage.
Watson et al. 30 have reported on the long-term outcome in a series of 30 males treated during childhood with cyclophosphamide in a dose of 2-3 mg/kg/body weight per day for a mean of 280 (range 42-556) days. The mean age at evaluation was 22 (range 17-29.5) years, mean age at treatment was 9.4 (2.9-17.3) years, and the mean time from completion of treatment to study was 12.8 (range 6.7-15.8) years. Of the 30 patients, four were azoospermic, nine were oligospermic (sperm count < 20 million/mL) and 17 were normospermic (sperm count >20 million/mL). Although there was no correlation between total testicular volume and sperm density, the three groups of patients differed significantly in mean testicular volume, with the azoospermic group having a notable reduction in testicular size. An inverse correlation was evident between sperm density and cyclophosphamide dosage in terms of duration of treatment and total dosage.
The reports of recovery of spermatogenesis in many of the patients previously treated with single cytotoxic drugs are encouraging. However, after certain combinations of cytotoxic drugs azoospermia seems to be permanent.
Whitehead et al.31 studied 74 men who had been treated for Hodgkin's disease. Of the 49 who received six or more courses of MVPP (mustine, vinblastine, procarbazine and prednisolone) and provided sperm, 42 were azoospermic. Five of the seven who showed evidence of spermatogenesis had a sperm count of < 1 million/mL. Furthermore, of 11 patients studied between 6 and 8 years after the end of chemotherapy, 10 were azoospermic. This strongly suggests that the chances of spermatogenesis recovering in the remaining patients must be extremely small. None the less, well-documented but isolated reports of such recovery exist. Combination chemotherapy has been a major therapeutic advance in the treatment of metastatic testicular cancer. Regimens of cis-diamine-dichloroproplatinum (CDDP), vinblastine and bleomycin have been shown to be effective in the treatment of metastatic teratoma. Patients with testicular cancer are usually young, and azoospermia is a common finding after completion of chemotherapy. Fortunately, recovery of spermatogenesis after therapy with CDDP, vinblastine and bleomycin is more likely than after MVPP; half the patients have a normal sperm count 3 years after completion of chemotherapy.
The cytotoxic drugs which damage the testis predominantly affect the germinal epithelium. However, investigations in men treated with MVPP for Hodgkin's disease suggest subtle impairment of Leydig cell function. The circulating testosterone concentration and the steroidogenic response to an acute bolus injection of hCG are normal. The basal LH concentration is frequently raised and the LH response to a GnRH test is exaggerated. The bioactive to immunoreactive LH ratio is normal and there is no disturbance of LH pulse frequency; however, the amplitude of the LH pulses is significantly raised. Because of this compensatory process, it has not usually been deemed necessary to offer androgen replacement in men with chemotherapy induced testicular damage. Lately, however, a substantial reduction in bone mineral density (BMD) has been reported in men who had received chemotherapy for Hodgkin's disease32. The reduction in BMD affected both cortical bone, measured at the forearm by single photon absorptiometry, and integral bone, measured at lumbar spine and femoral neck by dual energy X-ray absorptiometry. Furthermore there was a positive correlation between the serum testosterone level and the BMD standard deviation score at the lumbar spine and femoral neck, suggesting that a reduction in serum testosterone, as a consequence of chemotherapy-induced Leydig cell damage, is associated with a reduction in integral BMD. If confirmed by prospective studies, these observations will have therapeutic implications. Androgen replacement therapy may be required for men with low normal testosterone and a raised LH, even when sexual function is normal.
Gynaecomastia has been described after use of busulphan, vincristine, bischloronitrosourea as well as various combinations of cytotoxic drugs. It has been interpreted as a clinical manifestation of Leydig cell dysfunction associated biochemically with a subtle alteration of the circulating oestrogen:androgen ratio. It may be transient and is more likely to occur in those otherwise prone to developing gynaecomastia, such as the elderly.
Ovary
In the female, most of our information concerns the effects of cyclophosphamide on reproductive function. Uldall et al.33 studied 34 women with glomerulonephritis treated with daily cyclophosphamide for an average of 18 months. 18 women became amenorrhoeic an average of 7 months from starting cyclophosphamide. Periods returned in only one out of nine patients who had stopped taking the drug a mean of 12 months previously. Low urinary oestrogens and raised urinary gonadotropins suggested that the amenorrhoea was due to cyclophosphamide-induced ovarian damage. The amenorrhoea may or may not be permanent. Furthermore, the total dose of drug is likely to determine whether the amenorrhoea is reversible and how soon after initiation of treatment it will develop.
Susceptibility to cytotoxic-induced ovarian failure is age dependent. Koyama et al.34 studied women with breast carcinoma who had been treated with various cytotoxic drugs including cyclophosphamide. The average dose of cyclophosphamide given before the onset of amenorrhoea in patients in their forties, thirties and twenties was 5.2, 9.3 and 20.4 g, respectively. We might expect cytotoxicinduced ovarian failure to be rare in prepubertal and pubertal girls; however, clinical and morphological studies indicate that the young girl is not totally immune.
With the reduction in mortality rate from gestational trophoblastic tumours and Hodgkin's disease, there has been increasing interest in the impact of chemotherapy on reproductive function. Walden and Bagshawe35 analysed the reproductive performance of 314 women successfully treated for gestational trophoblastic tumours between 1962 and 1977; 159 of these patients had become pregnant despite previous treatment with methotrexate, 6-mercaptopurine, actinomycin D and 6-azauridine. Several groups have studied the incidence of amenorrhoea after MVPP or MOPP (mustine, vincristine, procarbazine and prednisolone) therapy for Hodgkin's disease, finding rates between 15% and 62%. In some the progression from regular menses to amenorrhoea is abrupt; in others there is a slow transition phase of oligomenorrhoea followed by a premature menopause.
Chaterjee et a].36 studied the acute effects of high dose chemotherapy or total body irradiation or both on ovarian function. Despite the different prospects for long-term recovery of ovarian function with the two forms of treatment, the acute hormonal changes were similar. Therefore, the severity of ovarian dysfunction occurring acutely after cytotoxic damage tells us little about the longterm prospect of recovery of ovarian function.
Most women with chemotherapy-induced ovarian failure under the age of 50 years should receive sex steroid replacement therapy with a preparation containing oestrogen and progestogen to prevent osteoporosis, to lessen the risk of ischaemic heart disease, and to alleviate symptoms in the symptomatic. A few women with a lesser degree of ovarian failure will produce enough oestrogen not to need replacement therapy.
CONCLUSIONS
The research potential of these iatrogenic endocrine disorders is high, with different patient cohorts providing a model for study of 'predictable' GH deficiency, early puberty and the possibility of new gonadal protection mechanisms to avoid gonadal toxicity.
Several odd observations remain to be explored. Why do we not see radiation-induced diabetes insipidus? Why, if gonadal steroidogenesis can be damaged by irradiation, is the adrenal gland inviolate? Why is GH secretion so vulnerable to radiation damage irrespective of whether the damage is directed at the hypothalamus or the pituitary?
There are unresolved clinical questions too. Which children with radiation-induced GH insufficiency will benefit most from GH replacement, and should therapy be continued into adult life? How can we predict the fertility potential and chances of recovery in a female patient with cytotoxic-induced ovarian damage? Do males with subtle Leydig cell dysfunction require androgen replacement therapy?
Finally who should look after this increasingly large cohort of patients in adult life? A reproductive endocrinologist, a gynaecologist or an endocrinologist with general interests?
